Titan Pharmaceuticals
Financials
Estimates*
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 6.6m | 3.6m | 4.8m | 1.5m | <1m | <1m | 7.1m |
| % growth | 2978 % | (45 %) | 34 % | (68 %) | (96 %) | (98 %) | - |
| EBITDA | (7.9m) | (17.9m) | (5.3m) | (9.8m) | (10.0m) | (8.9m) | - |
| % EBITDA margin | (119 %) | (497 %) | (110 %) | (642 %) | (16732 %) | (892000 %) | - |
| Profit | (9.0m) | (16.5m) | (18.2m) | (8.8m) | (10.2m) | (5.6m) | - |
| % profit margin | (136 %) | (456 %) | (377 %) | (575 %) | (17010 %) | (556900 %) | - |
| EV / revenue | 1.9x | 2.9x | 3.9x | 2.9x | 145.1x | 19.8x | - |
| EV / EBITDA | -1.6x | -0.6x | -3.5x | -0.5x | -0.9x | - | - |
| R&D budget | 7.5m | 7.2m | 5.9m | 5.7m | 4.8m | 1.9m | - |
| R&D % of revenue | 113 % | 201 % | 122 % | 373 % | 7930 % | 191300 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
$20.0m | Post IPO Debt | ||
| N/A | $5.0m | Post IPO Equity | |
$10.0m | Post IPO Debt | ||
* | N/A | $9.5m | Post IPO Equity |
| N/A | $9.7m | Post IPO Equity | |
N/A | Post IPO Equity | ||
* | N/A | $5.5m | Private Placement VC |
* | $9.5m | Post IPO Convertible | |
* | N/A | Acquisition | |
| Total Funding | €5.0m | ||
Related Content
Recent News about Titan Pharmaceuticals
EditTitan Pharmaceuticals is a specialty pharmaceuticals company focused on developing innovative therapeutics for chronic diseases. Utilizing its proprietary ProNeura platform, Titan offers long-term, continuous drug delivery solutions. The company's flagship product, Probuphine, is a six-month buprenorphine implant approved by the U.S. Food and Drug Administration for the maintenance treatment of opioid addiction. Titan operates in the pharmaceutical industry, targeting healthcare providers and patients requiring long-term medication management. The business model revolves around the development, approval, and commercialization of its drug delivery systems, generating revenue through product sales and potential partnerships. Titan's approach aims to provide stable, non-fluctuating medication levels, enhancing patient compliance and outcomes.
Keywords: specialty pharmaceuticals, chronic diseases, continuous drug delivery, ProNeura, opioid addiction, buprenorphine implant, FDA approved, healthcare providers, medication management, patient compliance.